tag:blogger.com,1999:blog-1136153439451224584.post1858138442930224566..comments2024-03-27T06:45:59.174-07:00Comments on Practical Fragments: Fragments in the clinic: 2015 editionDr. Teddy Zhttp://www.blogger.com/profile/07288045760981372367noreply@blogger.comBlogger5125tag:blogger.com,1999:blog-1136153439451224584.post-69628838235654175362015-12-19T13:25:25.469-08:002015-12-19T13:25:25.469-08:00Fresh from Pacifichem, ASTX660, Astex's cIAP/X...Fresh from Pacifichem, <a href="http://practicalfragments.blogspot.com/2015/08/fragments-vs-iaps-resisting-affinity.html" rel="nofollow">ASTX660</a>, Astex's cIAP/XIAP inhibitor, is now in a Phase 1-2 trial for advanced solid tumors and lymphomas.Dan Erlansonhttps://www.blogger.com/profile/07927082337051189270noreply@blogger.comtag:blogger.com,1999:blog-1136153439451224584.post-70210564379794986602015-05-20T06:06:46.339-07:002015-05-20T06:06:46.339-07:00Another update: ABL001, an allosteric Abl inhibito...Another update: ABL001, an allosteric Abl inhibitor from Novartis, is in a Phase 1 trial for CML and ALL - stay tuned for more details!<br /><br />Dan Erlansonhttps://www.blogger.com/profile/07927082337051189270noreply@blogger.comtag:blogger.com,1999:blog-1136153439451224584.post-59268571140537481272015-04-26T13:46:32.733-07:002015-04-26T13:46:32.733-07:00Just a few updates: PLX3397 is now in Phase 3, and...Just a few updates: PLX3397 is now in Phase 3, and Vernalis has an open phase 2 trial for their FAAH inhibitor V158866.Dan Erlansonhttps://www.blogger.com/profile/07927082337051189270noreply@blogger.comtag:blogger.com,1999:blog-1136153439451224584.post-35815301835533033732015-02-26T23:58:51.551-08:002015-02-26T23:58:51.551-08:00Navitoclax should be de-bolded. It was halted due ...Navitoclax should be de-bolded. It was halted due to dose-dependent thrombocytopenia. Its successor is ABT-199 (venetoclax), which also had a rocky time a couple of years ago when deaths due to tumor lysis syndrome triggered a clinical hold, but that problem seems to have been surmounted.DatamonitorMarkhttps://twitter.com/DatamonitorMarknoreply@blogger.comtag:blogger.com,1999:blog-1136153439451224584.post-63997749034808044402015-01-05T07:07:54.248-08:002015-01-05T07:07:54.248-08:00As a reminder, AStex was acquired by Otsuka, so up...As a reminder, AStex was acquired by Otsuka, so updates may be less frequent but may show up here:<br />http://www.otsuka.com/en/rd/pharmaceuticals/pipeline/<br /><br />Also, Novartis recently returned rights to AUY922 to Vernalis, placing its future highly in doubt given the shift in corporate strategy by Vernalis.BiotechDueDiligencehttp://www.biotechduediligence.comnoreply@blogger.com